Semaglutide, CKD and Australia

A September 2026 Australian multidisciplinary panel puts semaglutide into a broader type 2 diabetes and chronic kidney disease care plan, rather than presenting it as a stand-alone kidney treatment. Its starting point is the FLOW trial, where semaglutide reduced major kidney disease events by 24% versus placebo in people with type 2 diabetes and chronic kidney disease receiving background standard care^[2].

What the Australian panel adds

The panel article is a practical commentary for Australian clinicians. It discusses Therapeutic Goods Administration indications, Pharmaceutical Benefits Scheme restrictions, access barriers and shared care between primary and tertiary services. It describes glucagon-like peptide-1 receptor agonists, or GLP-1RAs, as one part of cardiorenal care alongside renin-angiotensin-aldosterone system blockade, sodium-glucose cotransporter-2 inhibitors and finerenone^[1].

That framing matters. Chronic kidney disease means lasting changes in kidney structure or function. In type 2 diabetes, albuminuria, meaning protein in the urine, and a falling estimated glomerular filtration rate, or eGFR, are common ways clinicians assess kidney involvement. The panel does not say that one medicine replaces the rest of a patient's treatment plan. It argues for sequencing therapies and coordinating care around the person's kidney, cardiovascular and diabetes risks^[1].

What FLOW tested

FLOW was a randomized, placebo-controlled trial in 3,533 people with type 2 diabetes and chronic kidney disease. Participants had reduced kidney function or higher urinary albumin, and the trial compared once-weekly subcutaneous semaglutide 1.0 mg with placebo. The study registry records it as a completed Phase 3 study sponsored by Novo Nordisk^[3].

The published result was not simply a change in a laboratory measure. The primary composite outcome included kidney failure, a sustained reduction of at least 50% in eGFR from baseline, or death from kidney-related or cardiovascular causes. Over a median 3.4 years of follow-up, 331 participants assigned semaglutide and 410 assigned placebo had a first primary-outcome event. The hazard ratio was 0.76, which corresponds to a 24% lower relative risk in the semaglutide group^[2].

FLOW also reported an 18% lower risk of major cardiovascular events and a 20% lower risk of death from any cause for semaglutide versus placebo. The annual eGFR slope was less steep by 1.16 mL per minute per 1.73 m² in the semaglutide group. These are trial findings in the enrolled population, not a prediction of an individual outcome^[2].

How to read the practical message

The panel identifies people with residual albuminuria, heart failure with preserved ejection fraction, established cardiovascular disease, obesity, and Aboriginal and Torres Strait Islander peoples at high cardiorenal risk as groups that may deserve careful consideration in a shared-care discussion. It also flags access and equity as live problems in Australia. That is a service and policy discussion, not a reason to self-select a prescription medicine^[1].

For a plain-English overview of the medicine itself, see our semaglutide guide. Its mechanism as a GLP-1 receptor agonist helps lower glucose in a glucose-dependent way, but treatment decisions in chronic kidney disease also involve kidney function, other medicines, adverse effects, access and the patient's priorities. The source paper is aimed at clinicians, and it repeatedly places those decisions in coordinated care^[1].

What this is not

The panel does not provide a universal dose plan for people with chronic kidney disease. It does not show that semaglutide alone prevents every kidney outcome. FLOW tested a particular population and compared a particular trial regimen with placebo on a background of guideline-directed therapy. The trial's eligibility criteria included defined eGFR and urinary albumin ranges, so its results should not be assumed to apply unchanged to every person with diabetes and kidney disease^[2].

The article also names important evidence gaps: non-diabetic chronic kidney disease, advanced chronic kidney disease, dialysis, transplant populations and equitable access. The authors identify those gaps as priorities for research and policy. A positive trial result does not settle those questions^[1]. The current evidence is strongest for the type 2 diabetes and chronic kidney disease population studied in FLOW. It should not be used to make claims about people on dialysis or after transplantation, because the panel lists those populations among the gaps.

Why this matters

The useful takeaway is narrower than a headline about a kidney benefit. FLOW supplies dedicated kidney-outcome evidence for semaglutide in type 2 diabetes and chronic kidney disease. The Australian panel turns that evidence into a question of care coordination, access and sequencing with other therapies. Readers considering semaglutide should discuss their individual kidney status and current medicines with the clinician managing their care, rather than treating trial averages as personal instructions. See the semaglutide regulation overview for the site's broader regulatory context. Our semaglutide safety summary covers the adverse-event context, and the evidence overview places FLOW beside other clinical research. Those pages describe the evidence; they do not substitute for individual clinical advice. A trial result is one input into a clinical conversation, alongside a person's medical history and the care already in place.